A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma

Kristopher J. Kimball*, T. Michael Numnum, Tyler O. Kirby, William C. Zamboni, Jacob M. Estes, Mack N. Barnes, Daniela E. Matei, Kevin M. Koch, Ronald D. Alvarez

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

32 Scopus citations


Objectives: To determine the maximum tolerated dose (MTD), spectrum of toxicities, clinical activity, and pharmacokinetics of carboplatin given in combination with lapatinib in women with a first recurrence of platinum sensitive epithelial ovarian carcinoma. Methods: Patients with measurable, platinum sensitive recurrent epithelial ovarian carcinoma were eligible. Cohorts of 3-6 patients were to receive up to 6 cycles of intravenous carboplatin AUC of 6 every 21 days in combination with escalating dosages of oral lapatinib (starting at a dose of 750 mg daily). Toxicity was assessed using NCI CTC for Adverse Events. Clinical response was monitored using RECIST criteria. Pharmacokinetic (PK) analysis was performed for the second cohort of patients. Results: Twelve patients were enrolled. No dose limiting toxicity was noted. Two of 6 patients in the first cohort had unanticipated excessive delays in treatment due to non-dose limiting G3 neutropenia. Therefore, the study was modified to reduce the carboplatin dose in the second cohort. The median number of courses administered to the 11 evaluable patients in these two cohorts was 2.8 (range 1-6). Drug-related grade 3 or 4 toxicities included non-dose limiting G4 thrombocytopenia (n = 1), and non-dose limiting G3 neutropenia (n = 3). Of the 11 patients who received ≥ 1 course of therapy, 3 (27%) had a partial response, and 3 (27%) had stable disease. The pharmacokinetics of carboplatin were not significantly altered by concomitant administration of lapatinib. Conclusions: This regimen of lapatinib and carboplatin was associated with unacceptable non-dose limiting toxicities, excessive treatment delays and limited clinical responses.

Original languageEnglish (US)
Pages (from-to)95-101
Number of pages7
JournalGynecologic oncology
Issue number1
StatePublished - Oct 1 2008


  • EGFR inhibitor
  • HER2 inhibitor
  • Lapatinib
  • Ovarian cancer

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology


Dive into the research topics of 'A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma'. Together they form a unique fingerprint.

Cite this